A Case of Morbihan Disease Successfully Treated With Abrocitinib Monotherapy

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Figure S1: Immunohistochemical findings in pre-treatment skin biopsy specimens. (a) LL-37 immunohistochemistry showing weak cytoplasmic positivity in the epidermis (basal and spinous layers) and in scattered dermal mononuclear cells. (b) CD4 immunohistochemistry showing that the majority of perivascular lymphocytes were CD4-positive. (c) IFN-γ immunohistochemistry showing cytoplasmic positivity in occasional mononuclear cells. (d) p-STAT1 immunohistochemistry showing strong nuclear positivity in a subset of dermal lymphocytes. (e) JAK1 immunohistochemistry showing negative expression in dermal inflammatory cells. (f) CD34 immunohistochemistry showing positive staining in dermal vascular endothelial cells, indicating vascular dilation. (g) LYVE-1 immunohistochemistry showing positive staining in dermal lymphatic endothelial cells, indicating lymphatic dilation. (h) CD68 immunohistochemistry showing occasional positive cells in the dermis. (i) Negative control (no primary antibody). Scale bars are shown in the figures. Table S1: Primary antibodies used for immunohistochemistry. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.